BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22694282)

  • 1. Glyburide ameliorates motor coordination and glucose homeostasis in a child with diabetes associated with the KCNJ11/S225T, del226-232 mutation.
    Battaglia D; Lin YW; Brogna C; Crinò A; Grasso V; Mozzi AF; Russo L; Spera S; Colombo C; Ricci S; Nichols CG; Mercuri E; Barbetti F
    Pediatr Diabetes; 2012 Dec; 13(8):656-60. PubMed ID: 22694282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.
    Slingerland AS; Nuboer R; Hadders-Algra M; Hattersley AT; Bruining GJ
    Diabetologia; 2006 Nov; 49(11):2559-63. PubMed ID: 17047922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Permanent neonatal diabetes mellitus due to KCNJ11 mutation in a Portuguese family: transition from insulin to oral sulfonylureas.
    Dupont J; Pereira C; Medeira A; Duarte R; Ellard S; Sampaio L
    J Pediatr Endocrinol Metab; 2012; 25(3-4):367-70. PubMed ID: 22768671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM.
    Mohamadi A; Clark LM; Lipkin PH; Mahone EM; Wodka EL; Plotnick LP
    Pediatr Diabetes; 2010 May; 11(3):203-7. PubMed ID: 19686306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional characterization of a novel KCNJ11 in frame mutation-deletion associated with infancy-onset diabetes and a mild form of intermediate DEND: a battle between K(ATP) gain of channel activity and loss of channel expression.
    Lin YW; Li A; Grasso V; Battaglia D; Crinò A; Colombo C; Barbetti F; Nichols CG
    PLoS One; 2013; 8(5):e63758. PubMed ID: 23667671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain.
    Shimomura K; Hörster F; de Wet H; Flanagan SE; Ellard S; Hattersley AT; Wolf NI; Ashcroft F; Ebinger F
    Neurology; 2007 Sep; 69(13):1342-9. PubMed ID: 17652641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and clinical features of K
    Hashimoto Y; Dateki S; Hirose M; Satomura K; Sawada H; Mizuno H; Sugihara S; Maruyama K; Urakami T; Sugawara H; Shirai K; Yorifuji T
    Pediatr Diabetes; 2017 Nov; 18(7):532-539. PubMed ID: 27681997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KCNJ11 in-frame 15-bp deletion leading to glibenclamide-responsive neonatal diabetes mellitus in a Chinese child.
    Yang W; Wei H; Sang Y
    J Pediatr Endocrinol Metab; 2013; 26(7-8):743-6. PubMed ID: 24266052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glibenclamide unresponsiveness in a Brazilian child with permanent neonatal diabetes mellitus and DEND syndrome due to a C166Y mutation in KCNJ11 (Kir6.2) gene.
    Della Manna T; Battistim C; Radonsky V; Savoldelli RD; Damiani D; Kok F; Pearson ER; Ellard S; Hattersley AT; Reis AF
    Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1350-5. PubMed ID: 19169493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First case of neonatal diabetes with KCNJ11 Q52R mutation successfully switched from insulin to sulphonylurea treatment.
    Ioacara S; Flanagan S; Fröhlich-Reiterer E; Goland R; Fica S
    J Diabetes Investig; 2017 Sep; 8(5):716-719. PubMed ID: 28083968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DEND Syndrome with Heterozygous KCNJ11 Mutation Successfully Treated with Sulfonylurea.
    Cho JH; Kang E; Lee BH; Kim GH; Choi JH; Yoo HW
    J Korean Med Sci; 2017 Jun; 32(6):1042-1045. PubMed ID: 28480665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.
    Mlynarski W; Tarasov AI; Gach A; Girard CA; Pietrzak I; Zubcevic L; Kusmierek J; Klupa T; Malecki MT; Ashcroft FM
    Nat Clin Pract Neurol; 2007 Nov; 3(11):640-5. PubMed ID: 17982434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AV59M KCNJ11 gene mutation leading to intermediate DEND syndrome in a Chinese child.
    Sang Y; Ni G; Gu Y; Liu M
    J Pediatr Endocrinol Metab; 2011; 24(9-10):763-6. PubMed ID: 22145471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial permanent neonatal diabetes with KCNJ11 mutation and the response to glyburide therapy--a three-year follow-up.
    Begum-Hasan J; Polychronakos C; Brill H
    J Pediatr Endocrinol Metab; 2008 Sep; 21(9):895-903. PubMed ID: 18924582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KCNJ11 in-frame 15-bp deletion leading to glibenclamide- responsive neonatal diabetes mellitus in a Chinese child.
    Yang W; Wei H; Sang Y
    J Pediatr Endocrinol Metab; 2013; 26(5-6):591-4. PubMed ID: 23640936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
    Bowman P; Sulen Å; Barbetti F; Beltrand J; Svalastoga P; Codner E; Tessmann EH; Juliusson PB; Skrivarhaug T; Pearson ER; Flanagan SE; Babiker T; Thomas NJ; Shepherd MH; Ellard S; Klimes I; Szopa M; Polak M; Iafusco D; Hattersley AT; Njølstad PR;
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):637-646. PubMed ID: 29880308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulfonylurea vs insulin therapy in individuals with sulfonylurea-sensitive permanent neonatal diabetes mellitus, attributable to a KCNJ11 mutation, and poor glycaemic control.
    Stanik J; Dankovcikova A; Barak L; Skopkova M; Palko M; Divinec J; Klimes I; Gasperikova D
    Diabet Med; 2018 Mar; 35(3):386-391. PubMed ID: 29278452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants.
    Mancioppi V; Pozzi E; Zanetta S; Missineo A; Savastio S; Barbetti F; Mellone S; Giordano M; Rabbone I
    Front Endocrinol (Lausanne); 2023; 14():1143736. PubMed ID: 37251668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
    Pearson ER; Flechtner I; Njølstad PR; Malecki MT; Flanagan SE; Larkin B; Ashcroft FM; Klimes I; Codner E; Iotova V; Slingerland AS; Shield J; Robert JJ; Holst JJ; Clark PM; Ellard S; Søvik O; Polak M; Hattersley AT;
    N Engl J Med; 2006 Aug; 355(5):467-77. PubMed ID: 16885550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful sulfonylurea treatment of an insulin-naïve neonate with diabetes mellitus due to a KCNJ11 mutation.
    Wambach JA; Marshall BA; Koster JC; White NH; Nichols CG
    Pediatr Diabetes; 2010 Jun; 11(4):286-8. PubMed ID: 19656320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.